Brooks Laboratories Share Price

Brooks Laboratories Investment Rating

• Master Rating:

• Brooks Laboratories has an operating revenue of Rs. 85.61 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of -26% needs improvement, ROE of -25% is poor and needs improvement. The company has a reasonable debt to equity of 15%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 13% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around 4% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 14 which is a POOR score indicating inconsistency in earnings, a RS Rating of 67 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 124 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.